Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row

News provided by
Crown Bioscience Inc.
Mar. 19, 2024 14:55
SAN DIEGO--(Business Wire / Korea Newswire)--Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, solidifies its stature as a frontrunner in the global healthcare sector by securing the T+ Employer® certification for healthcare excellence every year since the award was inaugurated in 2020.

This prestigious accolade, awarded by the Health Human Resources Development Center of the National Health Commission of China and MedTalent, highlights the company’s unwavering dedication to fostering a landmark corporate culture marked by inclusivity, innovation, and a seamless customer service.

The T+ Employer® certification celebrates Crown Bioscience’s impactful values and trendsetting role within the pharmaceutical, medical, life science, and virtual healthcare industries. This recognition is a testament to its pioneering leadership, which is validated through rigorous evaluation that includes enterprise research, professional public surveys, insights from key opinion leaders, and campus studies.

Company-wide initiatives such as significant contributions to oncology research and promoting cross-regional departmental collaboration via digitization and human systems have distinguished Crown Bioscience as a paradigm of employer excellence.

Shirley Huang, MBA, Senior Vice President of Human Resources, said: “The reaffirmation of the T+ Employer® certification is more than an accolade, it symbolizes the commitment of our talented team and the harmony with our values. In an ever-evolving industry landscape, this award is a testament to our ongoing efforts to merge our business goals with a supportive and thriving work culture.”

Launched by the MedTalent and Med+ Institute as the healthcare industry’s inaugural employer certification, the T+ Employer® certification has become a symbol of employment distinction and a beacon for healthcare businesses aspiring to excellence.

This achievement underscores Crown Bioscience’s dedication to setting high standards and pushing the boundaries of innovation across all facets of its business. It reflects the company’s strong resolve to enrich the work environment, consistently deliver beyond client expectations, and elevate industry standards.

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) partnering with biotech and pharmaceutical companies to rapidly advance the discovery and development of oncology drugs. As the exclusive preclinical CRO providing tumor organoid services with the well-established Hubrecht Organoid Technology, we offer over 600 organoid models spanning 22 cancer indications. Furthermore, we have developed the world’s largest commercially available PDX collection. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia. For more information, please visit

View source version on


View Korean version of this release


Crown Bioscience
Sarah Martin-Tyrrell